Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: emerging insights from clinical studies.

IF 3.2 4区 医学 Q3 CELL BIOLOGY
Jiya Jose, John D Hooper, Fernando Souza-Fonseca-Guimaraes
{"title":"Highlights of 2024. Broadening anti-cancer immunotherapy modalities with antibody-drug conjugates: emerging insights from clinical studies.","authors":"Jiya Jose, John D Hooper, Fernando Souza-Fonseca-Guimaraes","doi":"10.1111/imcb.70017","DOIUrl":null,"url":null,"abstract":"<p><p>In this article for the \"Highlights of 2024\" series, we discuss antibody-drug conjugates (ADCs), which are an emerging class of targeted cancer therapies that harness the specificity of monoclonal antibodies to deliver cytotoxic agents directly to tumor cells. ADCs bind to tumor-associated antigens, undergo internalization via receptor-mediated endocytosis, and release their cytotoxic payload intracellularly, reducing systemic toxicity. This highly selective mechanism has led to significant advancements in oncology, improving treatment efficacy while minimizing adverse effects.</p>","PeriodicalId":179,"journal":{"name":"Immunology & Cell Biology","volume":" ","pages":""},"PeriodicalIF":3.2000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunology & Cell Biology","FirstCategoryId":"2","ListUrlMain":"https://doi.org/10.1111/imcb.70017","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In this article for the "Highlights of 2024" series, we discuss antibody-drug conjugates (ADCs), which are an emerging class of targeted cancer therapies that harness the specificity of monoclonal antibodies to deliver cytotoxic agents directly to tumor cells. ADCs bind to tumor-associated antigens, undergo internalization via receptor-mediated endocytosis, and release their cytotoxic payload intracellularly, reducing systemic toxicity. This highly selective mechanism has led to significant advancements in oncology, improving treatment efficacy while minimizing adverse effects.

2024年的亮点。用抗体-药物偶联物扩大抗癌免疫治疗方式:来自临床研究的新见解。
在这篇“2024年亮点”系列文章中,我们讨论了抗体-药物偶联物(adc),这是一种新兴的靶向癌症治疗方法,利用单克隆抗体的特异性将细胞毒性药物直接递送到肿瘤细胞。adc与肿瘤相关抗原结合,通过受体介导的内吞作用内化,并在细胞内释放其细胞毒性载荷,降低全身毒性。这种高度选择性的机制导致了肿瘤学的重大进步,提高了治疗效果,同时最大限度地减少了不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Immunology & Cell Biology
Immunology & Cell Biology 医学-免疫学
CiteScore
7.50
自引率
2.50%
发文量
98
审稿时长
4-8 weeks
期刊介绍: The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信